You are here: Industry Insights > CARsgen Therapeutics

News List

CARsgen Therapeutics Appoints President of U.S. Ops contractpharma
January 17, 2022
Richard Daly brings 30 years of pharmaceutical industry experience, including leadership positions in multi-national corporations and biotech companies.
CARsgen Therapeutics Presents Updated Multiple Myeloma Cell Therapy Data at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition prnasia
December 07, 2020
CARsgen Therapeutics announced updated safety and efficacy results from its ongoing global clinical studies of CT053, an investigational chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed and/or refractory multiple myeloma (RRMM).
CARsgen Therapeutics Closes a USD 186 Million Series C Equity Financing to Accelerate Global Clinical Trials of its Cell Therapy Product Candidates prnasia
November 04, 2020
CARsgen Therapeutics Holdings Limited, a leading biotechnology company focused on innovation and development of chimeric antigen receptor (CAR) T-cell therapeutics, announced the completion of a USD 186 million Series C Equity Financing.
CARsgen Therapeutics Receives Positive EMA Opinion on Orphan Drug Designation for Fully Human Anti-BCMA CAR-T Cells (CT053) for the Treatment of Multiple Myeloma prnasia
April 27, 2020
CARsgen Therapeutics Co., Ltd., a clinical-stage biopharmaceutical company, today announced the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) adopted a positive opinion on CARsgen's application for orphan designation of it
CARsgen Therapeutics Receives IND Clearance from the NMPA for AB011 Humanized Claudin18.2 Monoclonal Antibody biopharmadive
December 10, 2019
CARsgen Therapeutics, a clinical-stage biopharmaceutical company committed to discovering and developing a combined.